An Open‐Label Randomized Controlled Non‐Inferiority Trial of Arginine Glutamate Injection for the Treatment of Mild Hepatic Encephalopathy
Both regimens effectively alleviated mild HE symptoms and reduced ammonia levels. Arginine glutamate showed non-inferiority to LOLA in terms of clinical improvement, ammonia reduction, and time to complete NCT-A, with no significant adverse events.
Authors
- Yuan Gao (ORCID: https://orcid.org/0000-0002-0670-9104)
- Wanli Kang (ORCID: https://orcid.org/0000-0002-3329-7096)
- Xian Yang (ORCID: https://orcid.org/0000-0003-4620-6170)
- Yun Yi Gao
- Rui Zhong (ORCID: https://orcid.org/0000-0002-6612-3260)
- Li Wang (ORCID: https://orcid.org/0000-0002-9838-1280)
- Lu Li (ORCID: https://orcid.org/0000-0003-1643-1684)
- Yu Chen (ORCID: https://orcid.org/0000-0002-1519-4894)
- Yan Ren (ORCID: https://orcid.org/0000-0002-4007-8625)
- Li Feng (ORCID: https://orcid.org/0000-0001-7658-1399)
- Ming Kong
- Hequn Zou (ORCID: https://orcid.org/0000-0002-7579-6643)
- Zhong Ping Duan
- Hai Bo Zhang
- Yu Tao Zhan
- Shuang Li (ORCID: https://orcid.org/0000-0002-1084-8887)
Institutions
- Beijing Tongren Hospital (CN)
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Red Cross Blood Center (CN)
- Beijing YouAn Hospital (CN)
Publication Details
- Journal
- Journal of Digestive Diseases
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1111/1751-2980.13355
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Municipal Natural Science Foundation
- National Key Research and Development Program of China